Modern Pharmacological Effect of Zhishi Xiebai Guizhitang： A Review
10.13422/j.cnki.syfjx.20221404
- VernacularTitle:枳实薤白桂枝汤现代药理作用研究进展
- Author:
Zhanzhan HE
1
;
Zhen YANG
2
;
Yujie QI
1
;
Xiangyun CHEN
2
;
Ying GENG
3
;
Zhenhong LIU
2
;
Xuguang TAO
1
;
Jing YU
1
;
Kaiyuan ZHANG
1
;
Ce CHU
1
;
Yulu YUAN
1
;
Wenlai WANG
1
;
Hongxia ZHAO
1
Author Information
1. Institute of Basic Theory of Traditional Chinese Medicine，China Academy of Chinese Medical Sciences，Beijing 100700，China
2. Beijing University of Chinese Medicine，Beijing 100029，China
3. Beijing Tongren Hospital，Capital Medical University，Beijing 100176，China
- Publication Type:Journal Article
- Keywords:
Zhishi Xiebai Guizhitang;
pharmaceutical chemistry;
pharmacological effects;
research progress;
review
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2023;29(6):254-259
- CountryChina
- Language:Chinese
-
Abstract:
Zhishi Xiebai Guizhitang is a classical prescription for the treatment of chest impediment with the method of warming Yang. It is included in the Catalogue of Ancient Classical Prescriptions issued by the National Administration of Traditional Chinese Medicine （First Batch）， with the effect of activating Yang， dissipating mass， moving Qi and resolving phlegm. Its main symptoms include chest fullness and pain， or even chest pain radiating to the back， wheezing， coughing， shortness of breath， and Qi reversal from the hypochondrium. In modern traditional Chinese medicine， Zhishi Xiebai Guizhitang is clinically used in the treatment of cardiovascular system， digestive system， respiratory system and other diseases， among which coronary heart disease， unstable angina pectoris， myocardial infarction， sinus bradycardia and other cardiovascular diseases have particularly significant effects. This paper reviewed the pharmacological studies of Zhishi Xiebai Guizhitang in the past 10 years. The results showed that each single medicine and the whole prescription alleviated the above cardiovascular diseases to a certain extent， with the pharmacological effects of improving intravascular environment， myocardial ischemia， myocardial ischemia-reperfusion injury， and myocardial hypoxia， anti-inflammation， plaque stabilisation， etc.， and the pharmacological mechanism involved the regulation of relevant active substances in vivo as well as related signaling pathways and ion channels， mainly including thromboxane B2 （TXB2）， prostacyclin I2（PGI2） and phosphatidylinositol 3-kinases/protein kinase B/endothelial nitric oxide synthase （PI3K/Akt/eNOS） signaling pathways， and ATP-sensitive potassium channels. In addition， the relationship between the pharmacological effects of some single medicines and transient receptor potential ankyrin 1 （TRPA1） has been reported that TRPA1 is a key to understanding the mechanism of Zhishi Xiebai Guizhitang in treating cardiovascular diseases， which is worth of further study.
